By Fineline Cube 
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300 mg tablets as a potential once-weekly (QW) oral formulation for pre-exposure prophylaxis (PrEP) to prevent HIV infection. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 2, 2027.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Application Type | Supplemental New Drug Application (sNDA) |
| Product | Yeztugo (lenacapavir) 300 mg tablets – once-weekly oral |
| Indication | Pre-exposure prophylaxis (PrEP) for HIV prevention |
| PDUFA Date | February 2, 2027 |
| Current Approval Status | Approved for initial loading dosing and as bridge to every-six-month injection |
Clinical Evidence – PURPOSE Trials
| Trial | Population | Key Findings |
|---|---|---|
| PURPOSE 1 | Cisgender women at risk for HIV | Demonstrated robust efficacy and safety profile |
| PURPOSE 2 | Cisgender men and gender-diverse individuals who have sex with men | Confirmed high efficacy across diverse global population |
| Combined Results | Global, diverse study population | Established lenacapavir’s well-characterized clinical profile for PrEP |
The pivotal PURPOSE 1 and PURPOSE 2 clinical trials fully demonstrated that lenacapavir has a robust and well-established clinical profile for PrEP, showing high efficacy across a diverse global population including cisgender women, cisgender men, and gender-diverse individuals.
Drug Profile & Innovation
- Molecule: Lenacapavir – first-in-class capsid inhibitor with long-acting properties
- Current Formulation: Every-six-month subcutaneous injection (approved)
- Proposed Innovation: Once-weekly oral tablet offering enhanced convenience and adherence
- Therapeutic Advantage: If approved, would become the first long-acting oral PrEP option, addressing adherence challenges associated with daily oral regimens
- Dosing Flexibility: Existing approval allows for oral tablets as initial loading dose and bridge therapy during injection delays
Market Impact & Strategic Significance
- PrEP Market Opportunity: U.S. PrEP market projected to reach USD 5.2 billion by 2028, with significant room for growth given that only ~30% of eligible individuals currently access PrEP
- Adherence Challenge: Daily oral PrEP regimens face adherence rates of 40–60%, while long-acting options could significantly improve consistent protection
- Competitive Landscape: Current PrEP options include daily oral tenofovir-based regimens (Truvada, Descovy) and the recently approved twice-yearly injectable Apretude (cabotegravir); once-weekly oral would fill a unique middle ground
- Revenue Potential: Analysts estimate peak annual sales of USD 1.8–2.5 billion globally if approved, assuming 25–35% market share capture among new PrEP initiators
Gilead’s sNDA submission represents a strategic expansion of its HIV prevention portfolio and demonstrates the company’s commitment to providing multiple prevention options tailored to diverse patient preferences and lifestyles.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory submissions, clinical development timelines, and commercial expectations for Yeztugo (lenacapavir). Actual results may differ due to risks including final FDA decisions, clinical trial outcomes, market adoption, competitive dynamics, and execution of Gilead’s commercial strategy.-Fineline Info & Tech